SMARCA2 and neoplasm: In contrast, Trp53 mutations that arose from all regions in Brm-negative tumors, regardless if they caused an inactivation of Trp53 function, failed to undergo selection and did not result in an increase in the percentage of tumor cells expressing a given Trp53 mutation.